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Abstract 
  
Background   
START (STrAtegies for RelaTives) intervention reduced depressive and anxiety symptoms of family carers of people 
with dementia at home over two years and was cost-effective. 
Aims 
To assess clinical-effectiveness over six years and impact on costs and care home admission.  
Methods  
We conducted a randomised, parallel group, superiority trial recruiting from 04/11/2009 to 08/06/2011 with six year 
follow-up. 260 self-identified family carers of people with dementia were randomised 2:1 to START, an eight-session 
manual-based coping intervention delivered by supervised psychology graduates or Treatment as Usual (TAU). The 
primary outcome was affective symptoms (hospital anxiety and depression total score; HADS-T), and secondary 
outcomes included patient and carer service costs, and care home admission. 
Results 
222 (85.8%) of 173 carers randomised to START and 87 to TAU, were included in the 6-year analyses. Over 72-months, 
the intervention group HADS-T scores were lower compared to TAU (adjusted mean difference -2.00; 95% Confidence 
Interval [CI]: -3.38 to -0.63).  In the final year, median patient-related costs were £5759 and £16964 (p=0.07), and 
median carer-related costs were £377 and £274 in intervention and TAU groups respectively. There were no significant 
group differences in time until care home admission [Intensity ratio START:TAU = 0.88 (CI: 0.58 to 1.35)]. 
Conclusions 
 START is clinically effective and this effect lasts for six years without increasing costs. This is the first intervention for 
which such a long-term clinical and possible economic benefit has been demonstrated. It has potential to make a 
difference to individual carers whilst not increasing costs.  
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Introduction  
Families provide most of the care to people with dementia living at home and family carers have worse physical health, 
more absences from work, lower quality of life and are more likely to be anxious or depressed than non-carers(1-4). 
Currently around 50 million people globally have dementia, projected to nearly triple by 2050, while the present 
annual global cost is US$818 billion(5). Nearly 85% of costs are family and social rather than medical costs(6). 
The START (STrAtegies for RelaTives) multicomponent intervention for family carers, individually delivered by 
supervised non-clinically trained psychology degree graduates, was tested by our research team in a randomised 
controlled trial and was the first to show both clinical-effectiveness (reduced anxiety and depressive symptoms, 
decreased depression caseness, improved quality of life) and cost-effectiveness for family carers of people with 
dementia(7, 8).  We found that START carers’ decrease in symptom score was greater than the minimum clinically 
important difference and at 8 months they were one fifth as likely to have case-level depression as controls. These 
benefits persisted for two years(9), when the intervention was also cost-neutral (9). To the best of our knowledge, 
there are no clinically and cost-effective interventions for family carers with effects known beyond five years(10) (11, 
12), and none are manualised; so the intervention can be delivered consistently to participants; by graduates without 
clinical training, with potential to implement at scale.   
Objectives 
Our aim is to determine the long-term (up to 6 years from baseline) clinical effectiveness of START for family carers’ 
affective symptoms and costs compared to Treatment as Usual (TAU) in terms of:  
 
1) Primary outcome 
o Total HADS score (hospital anxiety and depression total score; HADS-T) in carers of people with 
dementia  
2) Secondary outcomes  
o Anxiety and depression caseness and scores 
o Time until care home admission and death of the person with dementia  
o Time spent at home 
o Cost of care for both people with dementia and carers   
Methods 
We registered a trial protocol before recruitment began https://doi.org/10.1186/ISRCTN70017938. Methods and 
results up to two years follow-up are reported in detail elsewhere (7-9, 13, 14). We requested from funders and ethics 
committee, and were granted a no-cost extension to the trial, registered this with ISCTRN prior to analysis, to consider 
longer term outcome. The primary outcome was defined as repeated measures of the HADS-T. A standard reporting 
protocol was used.  
Intervention and delivery 
We developed the eight-session START manual-based individual coping intervention for dementia family carers from 
the American “Coping with Caregiving”(15). We trained and supervised psychology graduates to deliver the 
intervention (see supplementary figure 1), and PR supervised them clinically as a group with additional time 
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available for individual support. There was a strong practical focus in the training programme on how to deliver the 
therapy, potential clinical dilemmas, empathic listening, effective use of supervision, safe working practice and when 
to ask for help.  They were trained to adhere to the manual and we used role-play, with senior members of the team 
completing a competency checklist, to ensure they could deliver each session competently. We monitored 
intervention fidelity using a checklist out of a possible five points, and it was satisfactory. Therapists worked with 
carers to identify individual difficulties, find workable solutions rather than give answers or recommendations. They 
then implemented strategies including: behavioural management, communication strategies, identifying and 
changing unhelpful thoughts, positive reframing, accessing support, future planning and increasing pleasant events. 
Each session included a relaxation exercise and we asked carers to practice the individualised strategies and 
relaxation between sessions. The final session was used to agree a plan of what to do in future based upon what that 
carer had felt worked. The carer kept their own manual and relaxation CDs.   
In summary, START is a parallel-group, superiority, single-blind, randomised controlled trial (RCT) conducted in the UK 
(four sites). Participants were selected from varied clinical services, so we could see if the intervention was 
generalisable- a mental health trust in a large city; a trust in a semi-rural area, a tertiary neurological clinic for rare and 
young-onset dementia; and a mental health trust where patients were allocated to a specialist nurse (Admiral Nurse).  
We recruited 260 participants to the study, to fulfil the power requirements of the 8-month study. We recruited self-
identified family carers providing at least weekly support to people with a clinical diagnosis of dementia, living in their 
own homes and referred to the service we recruited from during the previous year. We excluded those who were 
unable to give informed consent or who lived more than 1.5 hours travelling time from the researchers’ base. We 
recruited from 04/11/2009 to 08/06/2011 through three mental health trusts and a tertiary neurology clinic. Last 
follow up was 28/04/2017. Standard treatment includes medical, psychological and social interventions, consisting of 
assessment, diagnosis and information-giving, risk assessment and management (e.g. fire, driving, adequate nutrition 
and self-care, vulnerability, managing money), drug treatment, cognitive stimulation therapy, practical support, 
treatment of neuropsychiatric and cognitive symptoms, assessment of capacity, help in making long-term decisions, 
and carer support. Patients in both groups received TAU and we have described service use in both groups in detail(16).  
Randomisation and masking 
Participants were randomised 2:1 to intervention: TAU, in order to maintain study power given the potential for 
clustering of outcomes by therapist in the intervention arm. Randomisation was stratified by centre using random 
permuted blocks via an online computer-generated randomisation system from an independent Clinical Trials Unit. 
Assessors were blinded to randomisation status, but study participants knew their allocation.  
Outcome measures 
We collected carer and patient socio-demographic details at baseline and we measured dementia severity using the 
clinical dementia rating (CDR)(17). We also administered the Neuropsychiatric Inventory (NPI)(18), as neuropsychiatric 
symptoms are associated with carer psychological morbidity, and the Zarit burden interview(19). Each item is scored 
as the product of severity and frequency giving a potential score of 0-12 and scores are summed giving a possible total 
from 0-144. Higher scores indicate more neuropsychiatric symptoms and more burden, respectively. We also 
measured carers’ anxiety and depressive symptoms, using the Hospital Anxiety and Depression Scale HADS(20, 21) at 
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baseline, 4, 8, 12 and 24 months. In an agreed extension with our funders and ethics committees, we continued to 
collect carer HADS scores and place of residence for patients six-monthly from 24 until 72 months.  We recorded the 
date that a patient was admitted to a care home or had died, and stopped measuring the HADS at that point.  HADS is 
a scale, validated for all age groups and settings, in people who are physically well or ill, and in Asian and African ethnic 
groups(19); summarised as HADS-D (depression) HADS-A (anxiety) with scores from 0 to 21 and a total HADS score 
(HADS-T) from 0 to 42 (higher scores indicating more symptoms).  The total score (HADS-T) is our chosen primary 
outcome as it has better sensitivity and positive predictive value than either of the individual scales in identifying 
depression, when compared to International Classification of Diseases (ICD) depression diagnosis criteria(21). HADS-
D and HADS-A are also validated as scores for “caseness” and were dichotomised as “case” and “non-case”, with a cut-
point of  ≥9 (19). 
The Client Service Receipt Inventory (CSRI)(22) measured health and social care service use retrospectively until 24 
months, but not beyond that point. Each carer reported their own and the patient’s service use over the previous 4 
months, covering the full range of services (8). Service contacts were multiplied by their unit costs (2009-10 prices) 
obtained from publicly available sources: NHS reference costs(23) for inpatient and outpatient attendances, and the 
PSSRU volume(24) for other services. Costs were discounted to present values at an annual rate of 3.5% (25). 
Statistical analysis 
Analyses were conducted based on a predefined statistical analysis plan. Most analyses were carried out using STATA 
(version 14), but some models (as detailed) were fitted using R. 
HADS scores 
HADS data included in the primary 72-month analysis are those collected while the carer was still actively looking after 
the patient (i.e. patient was still living at home). Data collected after the patient had died or was admitted to a care 
home was excluded.  
 
To be included in the primary long term analysis, the individual must have had at least one follow-up HADS-T score. 
Those excluded therefore have no follow-up measurements at any time point (so had died or withdrawn by 4 month; 
see consort diagram).  For those with available HADS-T data, we compare the group as randomised, regardless of the 
number of therapy sessions attended in the intervention group; an available case intention to treat analysis. 
 
We used mixed effects linear regression models to assess the effect of the START intervention on repeated 
measurements of HADS-T over 72 months.  Initially we adjusted for treatment centre, HADS-T at baseline and time 
but then extended this model to include adjustments for carer age, carer sex, baseline NPI score and Zarit score. We 
also investigated whether the treatment effect changed over time by including a treatment by time interaction.  We 
chose not to allow for therapist clustering in these models since previous analyses of data up to 24 months had 
indicated that clustering effects were negligible. As a sensitivity analysis however models were refitted allowing for 
therapist clustering. For all cases estimates obtained were not substantially different.  
We used scatter plots of residuals and fitted values to check model assumptions. The correlation structure assumed 
in the main analyses was compound symmetry; however, models were refitted in sensitivity analyses with alternative 
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structures (autoregressive (order 1) and linear spatial correlation assumptions). For all models these investigations 
supported the models used for the main analyses.   
Using logistic regression we also investigated whether those randomised subjects excluded from the modelling of 
HADS (i.e. those with no HADS outcome data) had significantly different baseline characteristics when compared with 
those included and planned to adjust the main analyses of HADS-T for such significant factors in a sensitivity analysis. 
These models identified baseline NPI and Zarit burden scores as significantly related to higher odds of dropping out 
(Odds ratio  (OR) 1.018;95% CI 1.001, 1.035;  OR 1.023 with 95% CI 1.002, 1.044 respectively. Adjustment for baseline 
NPI and Zarit scores did not substantially impact on the results. 
The analyses described for the HADS total score were repeated for anxiety and depression subscales of the HADS. 
We investigated the effect of the START intervention on the occurrence of cases of anxiety/depression, using mixed 
effects logistic regression models, with a participant-level random effect. 
If care home admission or death of the care recipient occurred prior to 72 months, the carer was not followed-up 
beyond the last visit prior to death or care home admission. Given the possibility of a relationship between HADS 
scores and death/care home admission, we conducted sensitivity analyses to consider the impact of such informative 
censoring. Joint mixed effect models for the longitudinal HADS scores and time to institutionalisation or death were 
fitted to account for the correlation between the longitudinal and survival outcomes(26). The HADS component 
treatment effect estimates were compared with those obtained from the previously fitted mixed models. [Note: Joint 
models were fitted using the JM package in R(27)].  
Time until care home admission 
We employed a multi-state model (depicted pictorially in supplementary Figure 2)(28) to analyse time until care home 
admission while accounting for the possibility of patient death.  The model was set up to allow transition from living 
at home to one of two states, care home admission or death. Effect estimates from the model are ‘intensity ratios’ 
which are analogous to hazard ratio estimates in a Cox proportional hazards model but pertain to the specific 
transitions within the multi-state model. As before, models were fitted adjusting for centre, carer age, carer sex, 
baseline NPI and Zarit score. [Note: Multi state models were fitted using the msm package in R(28)). 
Time spent at home 
In a further analysis of patient time spent at home (i.e. prior to care home admission or death), we fitted models for 
time to admission or death using a standard survival analysis. We used a log rank test to compare the randomised 
groups and then fitted a Cox regression model to provide a treatment effect estimate adjusted for centre, carer age, 
carer sex, baseline HADS total, baseline NPI total and Zarit total score. 
Costs  
Costs of services used by patients and carers were estimated up to the earliest of either their withdrawal from the 
study, death of either the patient or carer, or end of the follow-up period (72 months). For patients who remained at 
home, costs of NHS and social care services used by them or their carers were extrapolated from the last complete 
year of data (in most cases, 12-24 months post-randomisation). For patients admitted to care homes, unit costs of 
care home residence were applied for the duration of stay, and we assumed that carer service use costs would 
continue. Costs were carried forward as long as the patient/carer remained alive. In an initial analysis, the difference 
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in costs between treatment arms at 72 months was assessed statistically using the non-parametric Wilcoxon Rank-
Sum test(29). 
Patient involvement 
This study was devised and conducted with patient and public involvement (PPI) and representatives on the 
management and steering group. They helped shape the original questions, added qualitative questions about the 
experience and took part in interpreting the findings. They have also presented them.  
Results 
Participant flow and recruitment  
The Consort diagram (Figure 1) shows participant flow through the study. We randomised 260/472 (55%) of the carers 
referred; 173 (67%) participants to intervention and 87 (33%) to TAU. Others refused (n=181; 38%), did not meet 
inclusion criteria (n=22; 5%) or were uncontactable (n=9, 2%). The characteristics of the randomised groups generally 
achieved good balance in terms of socio-demographic and clinical characteristics (see supplementary table 1). Carers 
were mostly spouses/partners (109; 42%) or children (113; 44%). The proportions of patients who died (before they 
were admitted to a care home), were admitted to care homes and withdrew by randomised group is shown in 
supplementary table 2. There is no evidence of significant differences in the proportions of participants in each end-
status category between the START and TAU groups. 
Intervention adherence and fidelity 
130 (75%) carers in the intervention group attended ≥5 therapy sessions, 8 (5%) withdrew before any therapy sessions. 
Ten therapists delivered the intervention, to between 11 and 32 carers each. The mean fidelity score was 4.7 (SD 0.66). 
Primary outcome 
Table 1 summarises HADS-T scores at each follow-up point.  Analysis of HADS-T, adjusting for centre, baseline score, 
time and factors related to outcome (carer age and sex, NPI, Zarit) over the 6-year period, showed an average 
improvement in HADS-T of 2.00 points compared with TAU (95% CI: -3.38 to -0.63; p=0.005) (Table 2).  In the model 
adjusting only for centre, baseline score and time, average score decrease was smaller but still significant and in favour 
of the intervention group (Table 2). A model including an interaction with time showed no evidence of differential 
effects of the intervention over time (p=0.98). 
Secondary outcomes  
Depression and anxiety caseness and scores 
In the fully adjusted analyses there was a reduced odds of HADS-depression caseness in the intervention group 
compared to TAU, (OR =0.20 (95% CI: 0.08 to 0.52), p = 0.001). Reduction in HADS-anxiety caseness however was not 
significant (OR= 0.50, 95% CI: 0.24 to 1.07, p = 0.07) (Table 2).   
Fully adjusted models for HADS-A and HADS-D continuous scores indicated significant beneficial intervention effects 
over 6 years, with average decreases of -0.97 (95% CI= -1.78 to -0.15,) and -1.06 (95% CI-1.78 to -0.35) respectively. 
Models showed no evidence of differential intervention effects with time for HADS-A or HADS-D (p= 0.98 and p=0.94, 
respectively). 
 
Adjusted joint models were used as sensitivity analyses to  allow for the possibility of a relationship between HADS 
scores and time to care home admission or death gave similar results to previous models for HADS-T, HADS-D and 
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HADS-A (HADS-T: 2.01 (95% CI -3.38 to -0.63), HADS-D: -1.07 (-1.78 to -0.37)), HADS-A: -0.97 (-1.78 to -0.16)). This 
suggests that censoring by death/care home admission is not problematic.   
Analysis of time until patient care home admission and death 
Figure 2 shows the cumulative incidence of care home admission and death over time by randomised group. The multi-
state model adjusted for centre, carer age, carer sex, baseline HADS-T, baseline NPI and baseline Zarit gave intensity 
ratios for the START intervention versus TAU of 0.88 (95% CI 0.58 to 1.35) for the home-to-care-home transition and 
0.81 (95% CI 0.50 to 1.30) for the home-to-death transition.  
Analysis of time spent at home  
Based on Kaplan Meier estimates, the estimated median time spent at home (i.e. time until death or 
institutionalisation) for the TAU group was 39.0 months (95% CI 31.1 to 49.4) and for START was 42.2 months (95% CI 
33.3 to 54.7).  Cox regression with adjustments for centre, carer age, baseline HADS total, NPI score and Zarit score, 
showed no evidence of a difference between the randomised groups (hazard ratio estimate: 0.81 (95% CI 0.59 to 
1.11)). 
Costs  
Costs for carer and patient service use are shown in Table 3. Costs of services used by patients were much higher than 
costs for services used by carers across the full study period. In the final year of follow-up (61-72 months) median 
patient service use costs were £16,964 for TAU and £5,759 for START (p=0.072). Median carer service use costs were 
£377 for TAU and £274 for START. 
Discussion  
 
Main findings 
This is the first RCT to demonstrate that family carers of people with dementia referred to specialist care experience 
benefits from an intervention delivered by supervised psychology graduates in terms of depression and anxiety 
symptoms and depression caseness, not only in the short-term but for up to 6 years. The difference is small but is 
statistically significant, greater than the minimally clinically important difference (that which is clinically significant to 
patients)and is sustained(30). The difference in costs appears to be economically large (cost per patient in the 
intervention group is around a third of the cost in the treatment as usual group) although there was no significant 
difference in time to care home admission or death.  The reduced sample size, however, means that the test for 
differences in cost is underpowered (particularly given highly skewed cost data), but the estimated costs of health and 
care services used by patients appear to be lower for the intervention group compared to treatment as usual in the 
final year of follow-up.  It is encouraging that this intervention does not therefore increase costs, and might actually 
be cost-saving. Carers in the control group were five times more likely to have clinically significant depression on a 
rating scale validated against caseness using ICD criteria.  Predictably, health and social care costs increase over time 
for both groups, as a result of the worsening condition. There is a bigger increase in TAU group.  
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Strengths and limitations 
The trial is randomised, with blinded follow-ups. The intervention was manual-based, standardised and supervised. 
High fidelity ratings and very low inter-cluster correlations show the results do not differ according to therapists, 
suggesting that the intervention can be delivered consistently. 
We planned a pragmatic trial to include all family carers who presented to services so they had varied 
sociodemographic and clinical characteristics and came from a variety of services; consequently, our study has some 
external generalisability, that is, it suggests the intervention can be used in a  variety of NHS settings. We did not have 
the power to analyse whether this intervention was more effective in subgroups; for example, those with more 
education or without a mental health history or with more family support. As this is a follow up of the original trial we 
do not have any data on unintended harms but the service use and mortality data do not suggest harm. At the time of 
the START intervention most patients had only recently presented to services and thus the intervention can be offered 
at the beginning of the patient pathway but may not be applicable to those who have had the diagnosis for many 
years. It was preventative and improved depression and so can be offered to those with and without depression (7). 
START’s preventative effect highlights that carers can benefit from early intervention. A previously published 
qualitative analysis confirmed that carers used different components of the intervention and some continued to use 
these consciously over two years but we did not ask about this at six year follow up(14).  Only patient care home 
admission and death and carer HADS were directly collected after 2 years and therefore the economic analysis involved 
modelling. Although the differences in costs were striking, the nature of dementia which inevitably meant attrition by 
death of some of those with it over six years, meant the numbers were smaller. Additonally, the data was skewed and 
they only approached the usual level taken as significant.  
 
 Comparison with other studies, meaning and implications 
The practical nature of the intervention, in which carers were encouraged to develop and continue to use successful 
strategies, might also account for the longevity of the positive effects on carer mental health that we found – the most 
successful strategies were likely to be used repeatedly and therefore remembered and integrated into caring routines. 
The intervention included a final session on planning for the future. It is likely that the nature of caring difficulties will 
have evolved over six years. Intervention group participants were given a manual in which strategies they had found 
helpful for managing caring challenges, pleasant events were logged, and they were given relaxation exercises 
recordings, to refer to during future caring. 
Our findings suggest that carers were able to continue using the skills and strategies they had practised, in the longer 
term. A focus on planning for the future, accessing support, and explicit consideration of how difficulties may change 
and emotion-focused and acceptance-based strategies, might have helped support this. It is also possible that carers 
revisited previously less personally relevant aspects of the manualised intervention as certain issues or challenges 
became more salient to their caring. 
Many interventions for family carers of people with dementia have not worked in improving mood (31-33). Others 
have  been effective but the effects have not been sustained(34). Most have not considered prevention. In general 
those that have been effective are multicomponent and delivered to individuals rather than groups for at least six 
sessions (35) (36) and our study was designed to follow this model. Some earlier interventions for family carers have 
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been effective and had sustained effects which have continued for between one and  five years(10) (11, 12).  Our study 
is in line with this but because it is manual-based and delivered by non-clinically trained psychology graduates it is 
designed to be scalable and practical and has economic findings to support this. We have more fully considered cost 
than most other studies although there is some evidence that interventions can generate saving(37) (38). There is little 
evidence that carer stress predicts care home admission in community-dwelling older people in general (39) but 
psychological interventions for family carers may reduce care home admission for people living with dementia, with a 
meta-analysis of the best-quality studies finding a significant reduction in the odds of care home admission, although 
the time to admission difference did not reach significance(40).   Family carers become more anxious and depressed 
over time without intervention; thus we included carers who were not depressed at presentation (3, 4).  
Future research 
The START intervention is clinically effective, improving carer mood over six years. It does not increase patient or carer 
service-related costs and thus should be available. The numbers of people with dementia and the diversity of culture, 
geographic location and available resources mean that further research is necessary to widen access and optimise 
implementation. For example,  to  consider whether the intervention can be delivered remotely (through a skype or 
similar application), through existing voluntary sector carer support infrastructure (as some carers do not see 
themselves as patients) and be adapted for ethnic groups, different cultures and different countries.  
Word count 3996  
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 Figure 1: CONSORT diagram for long-term outcomes (up to 72 months)*. 
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Patient died (n=3) 
Patient care home admission (n=3) 
 
Further losses by 8 month follow-up (n=19) 
Withdrawn (n=11) 
Patient death since last follow-up (n=3) 
Patient care home admission since last follow-up (n=5) 
 
Further losses by 8 month follow-up (n=5) 
Withdrawn (n=4) 
Patient death since last follow-up (n=1) 
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Patient care home admission since last follow-up (n=8) 
 
Further losses by 30 month follow-up (n=22) 
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Declined participation in extension study (n=6) 
Patient death since last follow-up (n=3) 
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Further losses by 30 month follow-up (n=11) 
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Patient care home admission since last follow-up (n=1) 
 
4 month follow-up 
8 month follow-up 
12 month follow-up 
24 month follow-up 
30 month follow-up 
36 month follow-up 
42 month follow-up 
Enrolment 
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* HADS data included in the primary 72 month analysis are collected while the carer was still looking after the patient 
at home. Prior to 24 months, carers were followed up for HADS even after the patient had died or had been admitted 
to a care home. After 24 months, follow up was terminated when the patient died or was no longer at home. For the 
purposes of the six year follow-up analysis, observation of HADS has been censored for all patients if either death or 
care home admission occurred.  ** To be included in the primary long term analysis, the individual must have at least 
one follow up score available for the HADS total. 
  
Further losses by 42 month follow-up (n=6) 
Withdrawn (n=0) 
Patient death since last follow-up (n=2) 
Patient care home admission since last follow-up (n=4) 
 
Further losses by 42 month follow-up (n=2) 
Withdrawn (n=1) 
Patient death since last follow-up (n=1) 
Patient care home admission since last follow-up (n=0) 
 
Further losses by 48 month follow-up (n=5) 
Withdrawn (n=0) 
Patient death since last follow-up (n=3) 
Patient care home admission since last follow-up (n=2) 
 
Further losses by 48 month follow-up (n=6) 
Withdrawn (n=1) 
Patient death since last follow-up (n=2) 
Patient care home admission since last follow-up (n=3) 
 
Further losses by 54 month follow-up (n=5) 
Withdrawn (n=0) 
Patient death since last follow-up (n=4) 
Patient care home admission since last follow-up (n=1) 
 
Further losses by 54 month follow-up (n=2) 
Withdrawn (n=0) 
Patient death since last follow-up (n=1) 
Patient care home admission since last follow-up (n=1) 
 
Further losses by 60 month follow-up (n=6) 
Withdrawn (n=1) 
Patient death since last follow-up (n=2) 
Patient care home admission since last follow-up (n=3) 
 
Further losses by 60 month follow-up (n=2) 
Withdrawn (n=0) 
Patient death since last follow-up (n=2) 
Patient care home admission since last follow-up (n=0) 
 
Further losses by 66 month follow-up (n=6) 
Withdrawn (n=0) 
Patient death since last follow-up (n=1) 
Patient care home admission since last follow-up (n=5) 
 
Further losses by 66 month follow-up (n=2) 
Withdrawn (n=0) 
Patient death since last follow-up (n=1) 
Patient care home admission since last follow-up (n=1) 
 
Further losses by 72 month follow-up (n=4) 
Withdrawn (n=2) 
Patient death since last follow-up (n=1) 
Patient care home admission since last follow-up (n=1) 
 
Further losses by 72 month follow-up (n=3) 
Withdrawn (n=1) 
Patient death since last follow-up (n=0) 
Patient care home admission since last follow-up (n=2) 
 
Analysed for primary outcome (n=150) 
Excluded from primary analysis (n=23) 
 
Analysed for primary outcome (n=72) 
Excluded from primary analysis (n=15) 
 
48 month follow-up 
54 month follow-up 
60 month follow-up 
66 month follow-up 
72 month follow-up 
Primary Analysis** 
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Table 1: Summaries of HADS total score at each follow-up time by treatment group.  
Follow-up time 
(month) Group 
Number of 
observations (n) Mean (SD) 
0 
TAU 87 14.8 (7.4) 
START 172 13.5 (7.3) 
4 
TAU 70 14.3 (7.6) 
START 146 12.3 (7.3) 
8 
TAU 67 14.9 (8.1) 
START 125 12.8 (7.9) 
12 
TAU 57 15.1 (9.0) 
START 122 12.5 (7.8) 
24 
TAU 44 15.6 (8.7) 
START 93 12.7 (7.2) 
30 
TAU 33 15.5 (7.8) 
START 65 13.0 (7.5) 
36 
TAU 28 15.6 (7.5) 
START 65 12.3 (7.3) 
42 
TAU 27 15.7 (8.7) 
START 59 13.8 (8.0) 
48 
TAU 22 16.5 (8.9) 
START 54 13.2 (7.3) 
54 
TAU 20 16.2 (7.6) 
START 49 12.1 (7.0) 
60 
TAU 18 17.3 (10.3) 
START 44 12.3 (8.0) 
66 
TAU 15 15.1 (9.5) 
START 38 13 (7.9) 
72 
TAU 13 17.5 (11.1) 
START 34 12.5 (9.0) 
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Table 2; Estimates of the effect of the START intervention compared with TAU on HADS measures over 6 
years. 
HADS measure Estimates comparing intervention and TAU 
Adjusted for centre, baseline score 
and time (n=222) 
Adjusted for centre, baseline score, 
time, age, sex, NPI & Zarit (n=213) 
 Difference in means (95% CI) 
HADS-T (total score) -1.45 (-2.80 to -0.10) -2.00 (-3.38 to -0.63) 
HADS-D -0.93 (-1.63 to -0.24) -1.06 (-1.78 to -0.35) 
HADS-A -0.58 (-1.39 to 0.22) -0.97 (-1.78 to -0.15) 
 Odds ratio (95% CI) 
HADS-D caseness 0.30 (0.13 to 0.71) 0.20 (0.08 to 0.52) 
HADS-A caseness 0.64 (0.31 to 1.32) 0.50 (0.24 to 1.07) 
 
 
Table 3: Annual costs of services used by carers and patients, by year, from 25 to 72 months  
  Intervention Treatment as usual 
Time 
period 
Services for 
patient or 
carer 
N Median Inter-quartile 
range 
N Median Inter-quartile 
range 
25 to 36 
months 
Carer 82 364 132 to 704 35 269 103 to 622 
Patient 109 5764 1922 to 18,869 54 5303 1573 to 21,866 
37 to 48 
months 
Carer 83 402 130 to 702 35 279 166 to 601 
Patient 94 6098 1767 to 20,219 44 7200 1452 to 22,346 
49 to 60 
months 
Carer 73 390 137 to 666 28 274 178 to 587 
Patient 83 4619 1744 to 23,116 33 16,574 1524 to 24,920 
61 to 72 
months 
Carer 53 377 184 to 635 24 274 191 to 587 
Patient 68 5759 1892 to 18,254 30 16,964 2369 to 24,077 
Note: Differences between groups were tested using the non-parametric Wilcoxon rank-sum test. None were 
statistically significant, although the difference for 61-72 months approached statistical significance (p=0.0717). 
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Supplementary table 1: Baseline carer and patient demographic and clinical characteristics by randomisation group 
- Carer Patient 
 TAU (n=87) Intervention (n=173) TAU (n=87) Intervention (n=17  
Age (years)~ 
 
56.1 (12.3) 
range: 27,89 
62.0 (14.6) 
range: 18,88 
78.0 (9.9) 
range: 53,96 
79.9 (8.3) 
range: 55,95 
Sex*Female 62 (71.3%) 116 (67.1%) 50 (57.5%) 102 (59.0%) 
Ethnicity*White UK 65 (74.7%) 131 (76.2%) 61 (70.1%) 126 (72.8%) 
White other 5 (5.8%) 10 (5.8%) 6 (6.9%) 14 (8.1%) 
Black and minority 17 (19.5%) 31 (18.0%) 20 (23.0%) 33 (19.1%) 
Marital Status*Not 
currently married 
25 (28.7%) 61 (35.3%) 47 (54.0%) 92 (53.2%) 
Education*No 
qualifications 
18 (20.7%) 45 (26.0%) 44 (51.2%) 73 (44.5%) 
School level 33 (37.9%) 51 (29.5%) 16 (18.6%) 28 (17.1%) 
Further education 36 (41.4%) 77 (44.5%) 26 (30.2%) 63 (38.4%) 
Work *Full time 28 (32.2%) 36 (20.8%) n/a n/a 
Part time 20 (23.0%) 27 (15.6%) n/a n/a 
Retired 23 (26.4%) 80 (46.2%) n/a n/a 
Not working 16 (18.4%) 30 (17.3%) n/a n/a 
Living With Carer* n/a n/a 50 (57.5%) 113 (65.3%) 
Relationship to 
patient * Partner 
31 (35.6%) 78 (45.1%) n/a n/a 
Child 42 (48.3%) 71 (41.0%) n/a n/a 
Other 14 (16.1%) 24 (13.9%) n/a n/a 
NPI Total~ n/a n/a 26.6 (20.1)(n=86) 24.0 (19.0)(n=171  
CDR overall Score~ n/a n/a 1.3 (0.6) (n=87) 1.2 (0.6) (n=171) 
Zarit 38.1 (17.0)(n=84) 35.3 (18.4)(n=165) n/a n/a 
HADS-T score 14.8 (7.4) 13.5 (7.3) n/a  n/a 
HADS-A score 9.3 (4.3) 8.1 (4.4) n/a n/a 
16 
 
HADS-D 5.5 (3.9) 5.4 (3.8) n/a n/a 
QOL-AD  n/a n/a 29.9 (6.9) 30.2(6.9) 
HADS Anxiety Case(score 
of ≥9 )* 
48 (55.2%) 85 (49.4%) n/a n/a 
HADS Depression Case 
(score  ≥9)* 
17 (19.5%) 
 
36 (20.9%) 
 
n/a n/a 
Cost (£, over 4-month 
period pre-baseline) 
315 218 3205 2446 
HADS= Hospital Anxiety and Depression Scale, CDR =Clinical Dementia Scale MCTS= Modified Conflict Tactics Scale, Zarit = Zarit 
Burden Interview, NPI = Neuropsychiatric Inventory, Qol-AD = Quality of Life- Alzheimer’s disease, HSQ = Health Status 
Questionnaire ~ Data are mean (Standard deviation) *Data are number and percentage. If some people did not complete the 
measure n is indicated in the table. 
Supplementary figure 1: The START intervention 
 
 
 
  Each session includes:  
• Stress reduction 
exercises 
• Interactive exercises 
• Between session 
practice tasks 
• Recap on previous 
session  
• Record forms 
 
Delivered to individuals  
Each session lasts 60 
minutes 
Carers keep manual and 
add personal content in 
sessions 
Therapeutic approach: 
• Builds on existing 
skills and resources 
• Validates carers 
emotional 
experiences 
E    
COMMON ELEMENTS 
AND PROCESSES 
• Introduction to the course
• Overview of dementia
• Behaviour and emotion 
• Managing stress
Session 1: Stress and 
wellbeing
• Understanding the purpose of behaviour
• The Trigger-Behaviour-Reaction chain
Session 2: Reasons 
for behaviour
• Setting behavioural goals 
• Changing behaviours by changing reactions 
Session 3: Making a 
behaviour plan
• Further steps to changing behaviours
• Changing unhelpful thoughts
Session 4: Behaviour 
strategies and 
unhelpful thoughts
• How to express yourself effectively
• Practicing assertiveness skills
• Communicating with people with dementia
Session 5: 
Communication 
styles 
• Exploring options for care
• Managing your relative's physical health
• Legal issues in care planning
Session 6: Planning 
for the future
• How life effents affect mood
• identifying and planning pleasant events
• Monitoring your mood
Session 7: Pleasant 
events and your 
mood
• Review of intervention components
• Identifying what works
• Making a plan for the future
Session 8: Using your 
skills in the future
CORE SESSION 
COMPONENTS 
SESSION  
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Supplementary table 2: Summaries of patient death, care home admission, withdrawal and complete 
follow-up by treatment group.  End Status Number (Percentage) of participants per group All Participants 
 
TAU Group START Group P-value Death 21 (24.1%) 32 (18.5%) 53 (20.4%) 0.37 Care home admission 25 (28.7%) 58 (33.5%) 83 (31.9%) 0.52 Remain in study at 72 months and not known to have died or been admitted to care home 
13 (14.9%) 34 (19.7%) 47 (18.1%) 0.45 
Lost to follow up/withdrawal prior to 72 months 24 (27.6%) 43 (24.9%) 67 (25.8%) 0.75 Censored at 24 months due to non-participation in extension study 4 (4.6%) 6 (3.5%) 10 (3.8%) 0.74 Total 87  173  260   
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Supplementary figure 2 Multi-state model for patient care home admission and death. Direction of arrows represent 
the passage of time. 
 
λHI(t) denotes the instantaneous rate of transition from the ‘living at home’ state to the ‘care home admission’ state. 
λHD(t) denotes the instantaneous rate of transition from the ‘living at home’ state to the ‘death’ state  
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Supplementary Figure 3: Plot of estimated cumulative incidence functions for the events 
‘care home admission’ and ‘death’ over time, stratified by treatment group.  
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